i+Med S.Coop.
14
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Human In Use Test of GINHI-HP-009 in Healthy Adults
Role: lead
Human In Use Test of GINPI-HP-004 in Healthy Adults
Role: lead
Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions.
Role: lead
Efficacy and Safety of BtH Body 2.2% (Injectable Hyaluronic Acid) in Volumizing and Contouring Large Areas of the Body: Prospective Clinical Investigation.
Role: lead
Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.
Role: lead
Post-Market Study on the Safety and Effectiveness of the OpHLINE OVD in Cataract Surgery
Role: lead
Clinical Study on the Safety and Efficacy of an Injectable Hyaluronic Acid for Improving the Aesthetic Rejuvenation of the Vulvovaginal Area
Role: lead
Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.
Role: lead
Post-market Study on BtHCROSS® for Restoring Facial Volume After a Single Injection
Role: lead
Post-market Study on TrHCROSS® in Knee Osteoarthritis After a Single Injection
Role: lead
Post-marketing Study for the Evaluation of Profilm Mouth Sores
Role: lead
Clinical Trial to Assess the Effectiveness of I+Med's DayDrop Advanced Ophthalmic Drop
Role: lead
Post-marketing Study for the Evaluation of Profilm Cold Sores
Role: lead
Post-marketing Study Focused on Evaluating I+Med's DayDrop for Improving Signs and Symptoms of Mild/Moderate Dry Eye
Role: lead
All 14 trials loaded